For example, a Daratumumab (CD38 mAb approved by the FDA for the treatment of multiple myeloma) based ADC was shown to deliver DM4 specifically to CD38 overexpressing cancer cells [13]. The gene discussed is CD38; the disease is AL amyloidosis.